Search Results

« Previous | 1 - 10 of 16 | Next »

relevance date ▼ date ▲

Number of results to display per page

10 per page 20 per page 50 per page 100 per page

View results as:

List Slideshow

<span itemprop="name">Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes</span>

<span itemprop="name">Recombinant GPEHT Fusion Protein Derived from HTLV-1 Proteins with Alum Adjuvant Induces a High Immune Response in Mice</span>

<span itemprop="name">PDZ Proteins SCRIB and DLG1 Regulate Myeloma Cell Surface CD86 Expression, Growth, and Survival</span>

<span itemprop="name">Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing</span>

<span itemprop="name">Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy</span>

<span itemprop="name">Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-delta and -gamma</span>

<span itemprop="name">Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells</span>

<span itemprop="name">Engineering strategies to overcome the current roadblocks in CAR T cell therapy</span>

$<span itemprop="name">Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL</span>$

<span itemprop="name">Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance</span>

Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

1 of 16

Recombinant GPEHT Fusion Protein Derived from HTLV-1 Proteins with Alum Adjuvant Induces a High Immune Response in Mice

2 of 16

PDZ Proteins SCRIB and DLG1 Regulate Myeloma Cell Surface CD86 Expression, Growth, and Survival

3 of 16

Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing

4 of 16

Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy

5 of 16

Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-delta and -gamma

6 of 16

Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells

7 of 16

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

8 of 16

Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL

9 of 16

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

10 of 16

« Previous
Next »
1 Current Page, Page 1
2

Search

Search Constraints

Search Results

Limit your search

Authors

Date

Journal or Parent Publication Title

Type

Publication Version

Keyword